Posted by Michael Wonder on 29 Jun 2020
Cancer Prevention Pharmaceuticals submits new drug application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis
29 June 2020 - Company seeks accelerated approval for cancer drug.
Cancer Prevention Pharmaceuticals announced that it has submitted a new drug application to the U.S. FDA seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis.
CPP-1X/sul is a combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul). In a clinical trial in patients with large bowel polyps, the CPP-1X/sul combination prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo.
